

# 1<sup>st</sup> Quarter of Fiscal 2015 Financial Results Conference Call


August 3, 2015



## SGS2020 Rolling Plan (Targets for FY2017)



Our vision: Grow as a drug discovery-based pharmaceutical company









Sales and income on track

Operating income and ordinary income are higher than the levels achieved in the Apr. to Jun. period of any prior fiscal year

Increased Cymbalta<sup>®</sup> sales due to the modification of Cymbalta<sup>®</sup> contract with Eli Lilly Japan K.K.

Tivicay<sup>®</sup> and Triumeq<sup>®</sup> showing strong growth globally

Continued excellent development progress for late phase pipeline compounds





## Overview of 1<sup>st</sup> Quarter FY2015 Financial Results





#### 1Q FY2015 Results Financial Results (Consolidated)



(Units: B yen)

	FY2015	FY2015 FY2015 Progress		Progress vs.	FY2014	Y on Y	
	forecasts	1H forecasts	Apr-Jun results	forecasts (%)	Apr-Jun results	change (%)	change
Sales	296.0	138.0	63.9	46.3	62.7	1.8	1.2
Operating income	72.5	28.5	12.5	44.0	8.0	55.7	4.5
Ordinary income	79.5	28.0	14.6	52.2	13.6	7.1	1.0
Net income attributable to owners of the parent	52.0	17.0	9.7	56.8	10.3	(6.4)	(0.6)

Note: All numerical values are rounded to the nearest unit


 Operating income and ordinary income are higher than the levels achieved in the Apr. to Jun. period of any prior fiscal year

Exchange rate (average)	FY2015 forecasts	Apr-Jun results
USD (\$) – JPY (¥)	120	121.44
EUR (€) – JPY (¥)	130	134.20
GBP (£) – JPY (¥)	175	186.16



#### 1Q FY2015 Results Financial Position and Cash Flow (Consolidated)







#### 1Q FY2015 Results Statements of Income (Consolidated)



7

						is. D yell)
	FY2015		Progress	FY2014	Yo	nY
	1H forecasts	Apr-Jun results	vs. forecasts (%)	Apr-Jun results	change (%)	change
Prescription drugs	79.2	39.7	50.2	38.7	2.6	1.0
Total of 3 key products	37.2	18.2	48.9	17.1	6.3	1.1
Total of 8 strategic products	49.4	24.2	48.9	22.9	5.7	1.3
Overseas subsidiaries/export*	14.8	7.2	48.0	6.0	19.3	1.2
Shionogi Inc.	9.0	4.4	48.6	2.8	53.8	1.6
<b>O</b> sphena <sup>®</sup>	3.0	1.3	42.1	0.8	66.4	0.5
C&O	3.4	1.6	45.8	1.8	(11.9)	(0.2)
Contract manufacturing*	3.7	1.5	40.6	3.5	(57.6)	(2.0)
OTC and quasi-drugs	2.5	1.2	49.9	1.1	12.4	0.1
Royalty income	36.5	13.5	37.1	12.7	6.9	0.8
Royalty income for the sales of Crestor <sup>®</sup> and HIV franchise	32.0	12.6	39.5	11.8	7.3	0.8
Crestor <sup>®</sup>	-	11.2	-	11.8	(4.5)	(0.6)
HIV franchise	-	1.4	-	-	-	1.4
Others	1.3	0.7	56.2	0.7	(1.1)	(0.0)
Total	138.0	63.9	46.3	62.7	1.8	1.2

Eight strategic products: Crestor<sup>®</sup>, Irbetan<sup>®</sup> franchise, Cymbalta<sup>®</sup> (3 key products), and OxyContin<sup>®</sup> franchise, Finibax<sup>®</sup>, Differin<sup>®</sup>, Pirespa<sup>®</sup>, Rapiacta<sup>®</sup>




\* The accounting policy for API for dolutegravir was changed from export to contract manufacturing in FY2014

#### 1Q FY2015 Results US business: Osphena<sup>®</sup>



- Optimized promotional activities with greater precision and clarity in HCP audience focus and messaging
  - Increased patient adherence and accessibility by launching 90 count bottle and simplifying copay card offers, provided in both traditional and electronic formats
  - Standardized weekly review process with new KPIs
- Osphena normalized TRx is increasing and trending above market throughout 2015
  - Grew market share to nearly 5% in a declining VVA market




Accelerating Osphena<sup>®</sup> growth with new DTC campaign (start 2Q FY2015) and future additional indication for vaginal dryness (start Phase III study 3Q FY2015)



Normalized TRx: Recalculated the prescription of 90 count bottle to 30 count bottle Vaginal dryness: Symptom caused by reduced estrogen levels in vaginal tissue

### 1Q FY2015 Results HIV Franchise





- Sales of the HIV franchise continue to grow strongly worldwide
- Sales are also rapidly expanding in the Japanese market (Triumeq<sup>®</sup> was launched in Apr. 2015)
- Began receiving royalties for the HIV franchise in 1Q (previously expected in 2Q)
- Annual dividend from ViiV for CY2015 will be recorded in 4Q FY2015



#### 1Q FY2015 Results Japan: Sales of 8 Strategic Products



(Units: B yen)

**FY2015** Y on Y Progress vs. FY2014 Apr-Apr-Jun change forecasts (%) Jun results **1H forecasts** change results (%) 39.7 **Prescription drugs** 79.2 38.7 50.2 2.6 1.0 **Crestor**<sup>®</sup> 21.3 10.6 10.8 49.9 (1.8) (0.2)Irbetan<sup>®</sup> franchise 8.2 4.1 3.7 49.9 9.4 0.4 Cymbalta<sup>®</sup>\* 7.7 3.5 2.5 45.0 36.2 1.0 37.2 Total of 3 key products 18.2 48.9 17.1 6.3 1.1 **OxyContin<sup>®</sup> franchise** 5.3 2.7 2.6 48.7 (4.2) (0.1) **Finibax**<sup>®</sup> 1.9 1.0 0.9 11.7 51.3 0.1 Differin® 1.9 0.9 0.9 45.2 (2.6) (0.0)Pirespa<sup>®</sup> 3.0 1.6 52.2 1.3 24.1 0.3 **Rapiacta**<sup>®</sup> 0.1 (0.0)0.1 (0.1) = 49.4 24.2 **Total of 8 strategic products** 22.9 48.9 5.7 1.3 [percent of sales] [62.4] [60.8] [59.1] -



\* Remuneration for promotional activity from FY2015 10

#### 1Q FY2015 Results

## Japan: One of the Key Products - Cymbalta®



- Sales structure was changed to 1brand-1channel
  - Both Shionogi and Eli Lilly Japan K.K. strengthened their promotional activities
  - Sales of Cymbalta<sup>®</sup> brand are growing strongly
- Impact of the modification of Cymbalta<sup>®</sup> contract
  - Shionogi receives remuneration for promotion based on Cymbalta<sup>®</sup> sales
  - Decrease in cost of sales
  - ⇒Modification of the Cymbalta<sup>®</sup> contract is resulting in increased sales and reduced cost-of-goods


Additional indication for pain associated with fibromyalgia (May 2015)

Phase III	NDA	Approval	Launch		
Depression and depressive state (launched in Apr. 2010)					
Pain associated with diabet	ic neuropathy (additio	onal indication in Feb	. 2012)		
Pain associated with fibrom	yalgia (additional ind	ication in May 2015)			
Pain associated with chronic low back pain (NDA in Dec. 2014)					
Pain associated with osteoarthritis (NDA submission in preparation)					

Maximize the value of Cymbalta<sup>®</sup> by additional indications in pain area



#### 1Q FY2015 Results Change in Sales vs. Previous Year





S-O-N-G


#### 1Q FY2015 Results **Statements of Income (Consolidated)**



(Units: B yen)

	FY2	2015	Progress vs.	FY2014	Y on	Y
	1H forecasts	Apr-Jun results	forecasts (%)	Apr-Jun results	change (%)	change
Sales	138.0	63.9	46.3	62.7	1.8	1.2
[Royalty* income]	32.0	12.6	39.5	11.8	7.3	0.8
	25.6 [33.3]	28.3 [35.2]		31.6 [38.9]		
Cost of sales	35.3	18.0	51.1	19.8	(9.0)	(1.8)
Gross profit	102.7	45.8	44.6	42.9	6.8	2.9
	53.8	52.1		55.6		
SG&A expenses	74.2	33.3	44.9	34.9	(4.5)	(1.6)
Selling & general expenses	50.2	22.7	45.1	23.1	(1.9)	(0.4)
R&D expenses	24.0	10.6	44.3	11.7	(9.5)	(1.1)
	20.7	19.6		12.8		
Operating income	28.5	12.5	44.0	8.0	55.7	4.5
[Excluding royalty* income]	(3.5)	(0.1)	-	(3.7)	-	3.6
Non-operating income and expenses	L0.5	P2.1	-	P5.6	-	(3.5)
Ordinary income	<sup>20.3</sup> 28.0	<sup>22.9</sup> 14.6	52.2	<sup>21.7</sup> 13.6	7.1	1.0

Note: Small numbers in red are percent of sales, and numbers in red provided in parentheses are percent of sales excluding royalties \* Royalty income from AstraZeneca and ViiV for the sales of Crestor<sup>®</sup> and HIV franchise







# **Research & Development**





R&D

## **Target Milestones for FY2015 and Progress**



Areas	Code No.	Indication	Target milestone for FY2015	As of 6/30/2015
Infectious disease	S-649266	Severe gram-negative infections	Global: Phase III initiated	Phase II
	S-033188	Influenza virus infection	Japan: Phase I completed Go/No Go decision	Phase I
Pain/CNS		Pain associated with fibromyalgia	Japan: Approved	<u>(May 2015)</u>
	Cymbalta®	Pain associated with chronic low back pain	Japan: Approval	NDA submission (Dec. 2014)
		Pain associated with osteoarthritis	Japan: Phase III completed	NDA submission (in preparation)
	S-297995 (naldemedine)	Alleviation of opioid- induced adverse effects	US/Japan: NDA submission	Phase III
	OxyContin®	Cancer/Non-cancer pain (Abuse deterrent)	Japan: Phase I initiated	
	S-718632	Chronic pain (Abuse deterrent)	US: Decision on final formulation	Phase I
	S-877503	ADHD	Japan: NDA submission	NDA submission (in preparation)
Frontier	S-888711	Thrombocytopenia	Japan: Approval	NDA submission (Dec. 2014)



### R&D Infectious Diseases: HIV Integrase Inhibitor Franchise

Phase I	Phase II	Phase III	NDA	Approval	Launch
Tivicay <sup>®</sup> (dolutegrav	rir)				
Triumeq <sup>®</sup> (dolutegravir/abacavir/lamivudine)					
Dolutegravir + rilpiv	Olutegravir + rilpivirine Out-licensed to ViiV				
Cabotegravir LA + rilpivirine LA			Co-de	velopment of Vii\	/ and Janssen

#### Development of oral fixed dose combination tablet of dolutegravir (DTG) and rilpivirine (RPV)

- Phase I studies are now underway in healthy subjects for various test formulations of DTG+RPV to select the best fixed dose tablet
- Phase III study initiated in May 2015 to evaluate the antiviral activity, safety, and tolerability of switching to DTG (50mg) + RPV (25mg) compared to current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed (non-inferiority endpoint)


#### Development of long-acting injectable cabotegravir (S/GSK1265744)

- Phase IIb study to evaluate a long-acting intramuscular regimen (once a month, or once every 2 months) for maintenance of virologic suppression (following induction with an oral regimen of S/GSK1265744 and abacavir/lamivudine) in HIV-1 infected, antiretroviral therapy naïve subjects
- Phase IIa study for pre-exposure prophylaxis (once every 3 months injection, intramuscular); ÉCLAIR study in HIV uninfected men and HPTN077 study in uninfected men and women, to evaluate the safety, tolerability, and acceptability



S-O-N-G

for you!



Development of naldemedine, alleviation of opioid-induced adverse effects (COMPOSE program)

- Phase III studies are on-going: chronic non-cancer pain patients in the US and cancer and chronic noncancer pain patients in Japan
- Code-break of COMPOSE I, II, IV: Met the primary endpoints in all pivotal studies
- NDA submission in the US and Japan in Q4 FY2015
- Development of OxyContin<sup>®</sup> (non-cancer pain)
  - Obtained new indication requested for development by MHLW in Dec. 2010
  - Phase III study ongoing: the treatment of moderate to severe chronic pain
- Development of abuse-deterrent, tamper-resistant formulation of opioid
  - Clinical studies of abuse-deterrent, tamper-resistant oxycodone tablets for cancer pain and non-cancer pain are on-going
  - Entered into a global alliance for abuse-deterrent hydrocodone with Egalet (US: Phase I study)



S-O-N-G

#### R&D Pain/CNS: Top Line Results of COMPOSE Program



	COMPOSE I and II	COMPOSE IV	
Area	Global	Japan	
Drug	Naldemedine (0.2 mg tablet, once daily, 12W)	Naldemedine (0.2 mg tablet, once daily, 2W)	
Target patients	Chronic non-cancer pain patients	Cancer patients	
	Efficacy profile		
<u>Primary endpoint:</u> Proportion of responders	The treatment difference in responder rate between naldemedine and placebo was statistically significant		
<u>Secondary endpoints:</u> Frequency of SBM*s, CSBM**s, SBMs without strainings	The treatment differences in all secondary endpoints between naldemedine and placebo were statistically significant		
	Safety profile		
Tolerability	Generally w	ell tolerated	
TEAE***s (>= 5%)	Abdominal pain and diarrhea	Diarrhea	
Attenuation of opioid analgesic effects and withdrawal symptom	No significant changes were seen in the pain intensity NRS**** scores and COWS***** scores		



\*SBM: Spontaneous Bowel Movement, \*\*CSBM: Complete Spontaneous Bowel Movement, \*\*\*TEAEs: Treatment-19 Emergent Adverse Event, \*\*\*\*NRS: Numerical Rating Scale, \*\*\*\*\*COWS: Clinical Opiate Withdrawal Scale

R&D

### **Pipeline for Future Growth in the Japanese Domestic Market**



Phase I	Phase II	Phase III	NDA	Approval Launc
Cymbalta <sup>®</sup> (Pain associat	ed with fibromyalgia)			Approved: May 201
S-524101 (Allergic rhinitis	s caused by house-dust m	nite allergen)	Approved:	: Mar. 2015
Cymbalta <sup>®</sup> (Pain associat	ed with chronic low back	pain) NDA submission:	Dec. 2014	
S-888711 (Thrombocytop	enia)	NDA submission:	Dec. 2014	
S-877503 (ADHD)	N	IDA submission (in prepar	ation)	Steady
Cymbalta <sup>®</sup> (Pain associat	ed with osteoarthritis) N	IDA submission (in prepar	ation)	series of launches
S-297995 (Alleviation of o	pioid-induced adverse ef	fects)		in the
S-877489 (ADHD)				Japanese
OxyContin <sup>®</sup> (Moderate to	severe chronic pain; tam	per resistant formulation)		market
S-649266 (Severe gram-n	egative infections)			
S-033188 (Influenza virus	infection)			
	Infactious disease		Eropt	









# Next Actions to Achieve the Targets for FY2015 Business Plan Building on the Results of 1Q FY2015





#### Next Actions Building on the Results of 1Q FY2015 Results of 1Q FY2015



Good progress of Cymbalta<sup>®</sup> after the contract modification

- Both Shionogi and Eli Lilly strengthened their promotional activities
- Increase in sales
- Improvement in the cost of sales

Sales growth of Osphena<sup>®</sup> in the US

- New HCP messaging and focus
- Improvements in adherence and access
- Increased TRx (normalized to 30-count) and market share

### Growth of the HIV franchise

- Global sales growth
- Solid increase in royalty from ViiV

Steady progress on development program

- Continued excellent progress in naldemedine Phase III program
- Additional indications for Cymbalta<sup>®</sup>



#### Next Actions Building on the Results of 1Q FY2015 Challenges to Achieve FY2015 Business Plan Targets

Strengthening Japanese business as a business base Strengthening capability to support new global products Developing an operating structure independent of royalty income

- Further expansion of sales for Cymbalta<sup>®</sup>
- Achieve the sales targets of 8 strategic products
- Progress of pipeline to overcome the cliff in the Japanese market
- Further expansion of sales of Osphena<sup>®</sup> in the US
- Continue to accelerate global development of our original pipeline compounds

 Maintain tight controls over operating costs





# Appendix - Pipeline -



### Pipeline Changes in Pipeline (since May 2015)



Code No.  / Product name	Indication	Phase	Area	Changes
Approval				
Cymbalta <sup>®</sup>	Pain associated with fibromyalgia	Approval	Japan	NDA submission (Jun. 2014) → Approval (May 2015)
Endoxan <sup>®</sup>	Malignant lymphoma	Approval	Japan	NDA submission based on public knowledge (Feb. 2015) → Approval (Jun. 2015)
Predonine®	Malignant lymphoma	Approval	Japan	NDA submission based on public knowledge (Feb. 2015) → Approval (Jun. 2015)
Change of phase	e			
Cymbalta <sup>®</sup>	Pain associated with osteoarthritis	NDA submission (in preparation)	Japan	Phase III $\rightarrow$ NDA submission (in preparation)
S-525606	Allergic rhinitis caused by Japanese cedar allergen	Phase II	Japan	Phase I → Phase II
Change of indication				
S/GSK1265744 LAP*	For the treatment and prevention for HIV infection	Phase II	US	HIV infection $\rightarrow$ For the treatment and prevention for HIV infection



#### Pipeline Pipeline (as of Aug. 2015)



	Phase I Phase IIa Phase IIb	Phase III Filing/Approval
Infectious	S-649266 (Severe gram-negative infections) Global: Phas	e II Underline: Changes Red: Filing/Approval
diseases	S-033188 (Influenza virus Infection) Japan: Phase I	Blue: Change of Phase
	Cymbalta <sup>®</sup> (Pain associated with fibromyalgia)	Japan: NDA submission (Jun. 2014) → Japan: Approval (May. 2015)
	Cymbalta <sup>®</sup> (Pain associated with chronic low back pain)	Japan: NDA submission (Dec. 2014)
		mission (in preparation)
	Cymbalta <sup>®</sup> (Pain associated with osteoarthritis) $\frac{\text{Japan: F}}{\rightarrow \text{Japan}}$	<u>Phase III</u> n: NDA submission (in preparation)
	S-297995 (Alleviation of opioid-induced adverse effects)	
Pain/CNS	OxyContin <sup>®</sup> (Moderate to severe chronic pain)	Japan: Phase III
	S-877489 (ADHD)	Japan: Phase III
	S-120083 (Inflammatory pain) Japan: Phase I	
	S-010887 (Neuropathic pain) Japan: Phase I	
	S-718632 (Chronic pain) US: Phase I	1
	S-117957 (Insomnia) US: Phase I	1



#### Pipeline Pipeline (as of Aug. 2015)



	Phase I Phase IIa Phase IIb Phase III	
Metabolic	S-237648 (Obesity) Japan: Phase II	Underline: Changes Red: Filing/Approval
disorder	S-707106 (Type2 diabetes) US: Phase Ila	Blue: Change of Phase
	S-888711 (Thrombocytopenia) Global: Phase III, Japan: NDA subr	mission (Dec. 2014)
	S-588410 (Esophageal cancer) Japan:	Phase III
Eroption	S-555739 (Allergic rhinitis) EU: POM, US: Phase IIa, Japan:	Phase III
Frontier	S-525606 (Allergic rhinitis caused by Japanese cedar allergen) <u>Japan: F</u>	Phase I → Ph <mark>ase II</mark>
	S-588410 (Bladder cancer) Japan, EU: Phase II	Ì
	S-646240 (Age-related macular degeneration) Japan: Phase IIa	l
	S-488210 (Head and neck squamous cell carcinoma) EU: Phase I/II	1
	S-222611 (Malignant tumor) EU: Phase I/II	1
< Out-licensed>	S/GSK1265744 LAP* (HIV infection → For the treatment and prevention	n for HIV infection) US: Phase II
	Janssen/Shionogi BACE inhibitor (Alzheimer's disease) EU: Phase I	lla l



.

### **Forward-Looking Statements**



- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called "forward-looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

